Asia Cuanon Technology (603378.SH) intends to reduce its holding by a total of no more than 4.58% of the shares held by its controlling shareholder and actual controller.
Yashi Creativity (603378.SH) announced that its controlling shareholder, Shanghai Creativity Bright Investment Co., Ltd. (referred to as "Creativity...
Asia Cuanon Technology (603378.SH) announced that the company's controlling shareholder Shanghai Chuangnengming Investment Co., Ltd. (referred to as "Chuangnengming") and its concerted action person, the actual controller Li Jinzhong, plan to reduce their holdings of the company's shares by no more than 19.6225 million shares through the Shanghai Stock Exchange trading system in a centralized competitive bidding and bulk trading manner, which is equivalent to reducing no more than 4.58% of the total number of company shares. The reduction will be carried out within 3 months after the disclosure of the reduction plan, and the reduction price will be determined based on the market price at the time of implementation.
Related Articles

Ze Jing Co., Ltd. (02632) will be holding an initial public offering from March 16th to March 19th, planning to globally issue 16.2265 million H shares. It will introduce Yingke No.1 and Hong Kong High-Tech as cornerstone investors.

Qingdao TGOOD Electric (300001.SZ) won the bid for the Qinghai Oilfield Wind Power Project with a contract value of approximately 150 million yuan.

Chengdu Kanghua Biological Products (300841.SZ): ACYW135 Meningococcal Conjugate Vaccine Obtains Clinical Trial Approval Letter
Ze Jing Co., Ltd. (02632) will be holding an initial public offering from March 16th to March 19th, planning to globally issue 16.2265 million H shares. It will introduce Yingke No.1 and Hong Kong High-Tech as cornerstone investors.

Qingdao TGOOD Electric (300001.SZ) won the bid for the Qinghai Oilfield Wind Power Project with a contract value of approximately 150 million yuan.

Chengdu Kanghua Biological Products (300841.SZ): ACYW135 Meningococcal Conjugate Vaccine Obtains Clinical Trial Approval Letter






